Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.68 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.57 |
| ▸ | PRKACA | P17612 | 7/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878885 | 0.94 | MAPK14 (0.69) | MAPK14ROCK1PRKACACYP3A4MAPK9 | |
| SCHEMBL1876160 | 0.92 | MAPK14 (0.76) | MAPK14ROCK1PRKACACYP3A4MAPK9 | |
| SCHEMBL1877622 | 0.91 | MAPK14 (0.57) | MAPK14ROCK1PRKACACYP3A4MAPK9 | |
| SCHEMBL1877952 | 0.91 | MAPK14 (0.68) | MAPK14ROCK1PRKACACYP3A4MAPK9 | |
| SCHEMBL1884134 | 0.89 | MAPK14 (0.77) | MAPK14ROCK1PRKACACYP3A4MAPK9 | |
| SCHEMBL1878129 | 0.89 | MAPK14 (0.71) | MAPK14ROCK1PRKACACYP3A4MAPK9 | |
| SCHEMBL1876679 | 0.88 | MAPK14 (0.66) | MAPK14ROCK1PRKACACYP3A4MAPK9 | |
| SCHEMBL1880725 | 0.88 | MAPK14 (0.76) | MAPK14ROCK1PRKACACYP3A4MAPK9 | |
| SCHEMBL1878659 | 0.88 | MAPK14 (0.70) | MAPK14ROCK1PRKACACYP3A4MAPK9 | |
| SCHEMBL1879602 | 0.88 | MAPK14 (0.70) | MAPK14ROCK1PRKACACYP3A4MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1832584-B1 | PYRIMIDINYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-7939536-B2 | 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20080114003-A1 | Pyrimidinylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1832584-A1 | PYRIMIDINYLISOXAZOL DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114003-A1 | Pyrimidinylisoxazole Derivatives | MAPK3, MAPK7, MAP3K7 | MAPK14 29/4885ROCK1 399/4885PRKACA 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.